** Brokerage Leerink Partners raises PT on drugmaker Gilead Sciences GILD.O to $114 from $105
** Brokerage says it does not anticipate any "major top- or bottom-line surprises" in GILD's earnings, ahead of its Q2 results likely to be reported in early August
** Maintains "outperform" rating
** The new price target represents a 3.97% upside to the stock's last close
** Aside from earnings, brokerage says "the central focus will be on two recent HIV PrEP and treatment pipeline developments"
** Brokerage says GILD's recently approved twice-yearly injectable HIV PrEP, Yeztugo, can quickly and widely become available, considering its lower price compared to its once-daily PrEP drug, Descovy, and its efficacy even though unclear guidelines after U.S. top court ruling on preventative coverage and CMS
** Twenty of 30 brokerages rate the stock "buy" or higher, 10 "hold"; their median PT is $118.50 - data compiled by LSEG
** Up to last close, stock up 18.7% YTD
(Reporting by Siddhi Mahatole)
((siddhi.mahatole@thomsonreuters.com))
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。